Paul Leo

Dr Paul Leo serves as the Clinical Genomics Domain Leader at the Centre for Genomics and Personalised Health. He holds a PhD in Physics from James Cook University of North Queensland. His work focuses on translating genomic insights into clinical applications, particularly in cancer diagnostics and autoimmune disease research.

Education:

• PhD in Physics, James Cook University of North Queensland

Research Interests: Dr Leo’s research spans clinical genomics, cancer biomarkers, and genetic diagnostics. He develops innovative technologies like conductometric biosensors and SLIMamp NGS to improve molecular testing accuracy in challenging samples. His studies explore genetic drivers of diseases such as glioblastoma, ankylosing spondylitis, and acute myeloid leukemia (AML), emphasizing actionable insights for personalized therapies. He also investigates metabolic profiling in cancers and immune dysfunction linkages in spondyloarthropathy.

Articles Trends: Recent publications highlight advancements in ctDNA analysis for head and neck cancers, proteomic biomarker discovery in glioblastoma, and the role of genetic variants (e.g., ATM, Runx3) in cancer and autoimmune pathogenesis. He prioritizes clinical utility, with work on reducing sample QC failure rates and optimizing molecular testing protocols for real-world healthcare settings.

Labs/Teams: Leads the Clinical Genomics domain within the Centre for Genomics and Personalised Health, collaborating with institutions like Princess Alexandra Hospital (PAH) to advance molecular screening programs like the MoST study.